[Disclosure] Alteogen(196170) Resolves to Submit Agenda for Conditional KOSDAQ Delisting and KOSPI Transfer to Shareholders’ Meeting

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-06

Disclosure Type: Decision to Submit Agenda for Approval of Delisting

💡 3-Second Summary

Alteogen has resolved through its board of directors to submit an agenda for a conditional KOSDAQ delisting—aimed at transferring its listing to the KOSPI market—to the upcoming extraordinary general meeting of shareholders on December 8.

📊 1. [Key Disclosure Content & Summary of Major Figures]

This disclosure pertains to the board’s resolution to place the transfer listing to the KOSPI market on the agenda for an extraordinary general meeting of shareholders.

• Purpose of Delisting: Listing on the KOSPI Market
• Shareholders’ Meeting Schedule: December 08, 2025, at 09:00 AM (KST)
• Shareholders’ Meeting Venue: Medium Conference Room, 1st Floor, Daejeon Convention Center (DCC), 107 Expo-ro, Yuseong-gu, Daejeon, Korea
• Board Resolution Date: November 06, 2025 (2 out of 2 outside directors attended, auditor attended)
• Future Schedule: If the agenda is approved at the extraordinary general meeting of shareholders, the company plans to pursue a conditional delisting from KOSDAQ and proceed with the listing process on the KOSPI market, contingent upon regulatory approval.
• Share Distribution Status (As of September 30, 2025):
  • Largest Shareholder (Soon Jae Park) and Specially Related Parties: 10,891,700 shares (20.36%)
  • Shareholder with a 5% or Greater Stake (In Woo Hyung): 2,700,000 shares (5.05%)
  • Other Shareholders: 39,914,088 shares (74.59%)

📈 2. [Expert View: What This Disclosure Means for Investors]

• Resolutions & Contents: Alteogen’s board has decided to submit the agenda for conditional delisting from the KOSDAQ market for the purpose of a KOSPI transfer listing to an extraordinary general meeting of shareholders. If approved at the meeting, the transfer process will officially begin.
• Omitted Information in Disclosure: This disclosure does not specify concrete subsequent timelines, such as the planned submission date for the KOSPI preliminary listing application, the Korea Exchange’s screening schedule, or the exact date for the commencement of trading on KOSPI.
• Investor Interpretation: Since this is a board-level decision to propose the agenda, the actual transfer listing is strictly dependent on the approval at the extraordinary general meeting of shareholders on December 8, followed by subsequent approval from the relevant regulatory authority (Korea Exchange). These schedules and processes may change (may change) depending on the voting outcomes and regulatory reviews, meaning they should not be treated as absolute facts, and investors should verify the final execution through future progress disclosures.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s board has resolved to place the conditional KOSDAQ delisting agenda for a KOSPI listing transfer before the extraordinary general meeting of shareholders on December 8. Specific execution timelines, including the filing date for preliminary reviews or target listing dates, are not specified within this official disclosure. A board resolution to submit an agenda represents only the initial phase of a transfer listing, and the final timeline may be adjusted (may be altered) depending on the shareholder vote and regulatory screening results. Therefore, a measured approach involves tracking the outcome of the December shareholders’ meeting and the subsequent review procedures. This commentary outlines objective metrics and does not constitute any buy or sell signals.

📢 Disclaimer & Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.